ESTRO 36 Abstract Book

S521 ESTRO 36 2017 _______________________________________________________________________________________________

concurrent Cisplatin and 5-Flurouracil followed by, 10Gy/2Fr of ILBT boost once weekly. The patients with local advanced disease for palliation received 36Gy/12Fr through EBRT followed by, 10Gy/2Fr of ILBT once weekly. The outcome of treatment was assessed in terms of dysphagia score, dysphagia free survival, toxicities and overall survival. Results Median age of patients was 55 years. Histopathologically 96 % has Squamous cell carcinoma. 16 (64%) of patients were treated with definitive radiotherapy while the rest, 9 (36%) with palliative intent. At a median follow up of 9 months, 13 patients were dysphagia free and there were 5 deaths. One month after completion of treatment, 18 patients were dysphagia free while, 2 patients had partial relief and 5 patients did not notice any relief in dysphagia. 2 patients died within 6 months of completion while, 2 patients developed trachea-esophageal fistula during follow-up.

Twenty patients with different sites and grades of Soft Tissue Sarcoma underwent surgery and Intraoperative catheter implantations in single plane in biopsy proven Soft tissue sarcoma cases. These patients then underwent High Dose Brachytherapy with Iridium – 192. The patients received average dose of 3.5Gy per Fraction (Two fractions per day 6 hours apart) with total dose of 35 Gy/10 Fr/5 Days and after completion of treatment were followed up at 1 month and later every 3 monthly for 2 years; Followed by 6 monthly interval. Results The Patients were followed up for range of 6 – 42 months (Median 25 months) and overall control rate was 72.72%. The Local recurrence was noted in only one patient (9.09%) and two patients developed distant metastases (18.18%). The dosimetric outcomes were assessed and results analyzed related to the dose to the surrounding organs at risk. The quality of life parameters were also assessed prior to treatment and later during follow ups and results showed better quality of life parameters. Conclusion The results in our study suggested the importance of HDR Brachytherapy in management of Soft Tissue Sarcoma. The local control rate was 72.72 %. The dose of 35Gy over 10 fractions over 5 Days was found to be effective in local control and limb salvage in case of Soft Tissue Sarcoma as practiced at our Centre. PO-0950 High-dose-rate brachytherapy treatment in T1-T2 stage non-melanoma skin cancer patients. M.A. González Ruiz 1 , J. Quirós Rivero 1 , M.F. Ropero Carmona 1 , A. Ruiz Herrero 1 , M.C. Cruz Muñoz 1 , P. Simón Silva 1 , J.J. Cabrera Rodríguez 1 , J.L. Muñoz García 1 , Y. Ríos Kavadoy 1 , F. García Urra 1 , P. Almendras Manzano 2 1 Infanta Cristina Hospital, Radiation Oncology, Badajoz, Spain 2 Infanta Cristina Hospital, Radiophysics, Badajoz, Spain Purpose or Objective To analyze the results in terms of overall survival (OS), cancer specific survival (CSS), local control (LC), cosmesis and toxicity in patients (pts) with non-melanoma skin cancer (NMSC) treated with high-dose-rate brachytherapy (HDR-BT) treatment, plesiotherapy modality; with radical or adjuvant intention in our hospital. Material and Methods Retrospective study of 50 pts with 63 NMSC lesions, T1 (74%) and T2 (26%) stage treated from May 2015 to May 2016. HDR-BT treatment (6 Gy/fraction; total dose 42 Gy) was used in 48 pts with an equivalent 2 Gy dose (EQD2) of 56 Gy. Median total dose of HDR-BT was 42.6 Gy (range 36-50). All the lesions for the selected cases were limited 3-4 mm depth. Treatment intention was radical in 86% pts and adjuvant in 14% pts. The median age of the pts was 76 years-old (range 52-94); 64% males. Basal-cell carcinoma (84%) and face (92,4%) were the most frequent histological type and location respectively. The 34% of the lesions were treated with Valencia applicators and 66% with custom-made moulds. Kaplan-Meier curves have been used for the statistical analysis of survival. Treatment- related toxicity was assessed using RTOG and the NCI- Common Terminology Criteria for Adverse Events guidelines. Results The median follow-up was 18 months (range 7-45). The OS, CSS and LC was 96%, 100% and 96% respectively. The majority of pts had acute skin toxicity grade 1-2. Conjunctival toxicity appeared in 10 % of the pts. Cosmetic results were considered as excellent/good in all patients. Conclusion In patients with NMSC T1 and T2 stage HDR-BT treatment, plesiotherapy modality is a good alternative treatment for non-surgical patients. Plesiotherapy treatment provides excellent results for local control and cosmesis which is a safe and attractive treatment option.

Conclusion ILBT is a safe modality for boost in treatment of carcinoma esophagus provided, the patients are sele cted with caution. PO-0949 Evaluation of role of Interstitial Brachytherapy in Soft Tissue Sarcoma: Single institute experience V. Pareek 1 1 Jupiter Hospital- Thane, Radiation Oncology, Mumbai, India Purpose or Objective Soft tissue Sarcomas are rare group of solid tumors comprising of 1% of all solid tumors. The management of soft tissue sarcomas have evolved due to advancements in imaging, histopathology, cytogenetics, and the use of multimodality treatment. The treatment strategies emphasizes on the control of disease locally, sparing of limb function and improvement in the quality of life. High dose brachytherapy has formed a part of the management and has the advantage of providing concentrated dose to tumors and sparing of surrounding normal tissues. In this study we examined the clinical outcome of High dose Brachytherapy for STS at our Hospital through retrospective analysis of the prospective database maintained. Objectives: To review the clinical outcome and quality of life in patients with Soft Tissue Sarcoma treated at our center through High dose rate interstitial brachytherapy. Material and Methods